<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924089</url>
  </required_header>
  <id_info>
    <org_study_id>PI18/01041</org_study_id>
    <nct_id>NCT03924089</nct_id>
  </id_info>
  <brief_title>Oral Nutritional Supplement on Nutritional and Functional Status, and Biomarkers in Malnourished Hemodialysis Patients.</brief_title>
  <acronym>RENACARE</acronym>
  <official_title>Effect of an Oral Nutritional Supplement on Nutritional and Functional Status, Biological Markers (Inflammation and Oxidative Stress, Intestinal Microbiota, Circulating microRNA and Its Target Genes) in Malnourished Hemodialysis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malnutrition in hemodialysis patients is frequent and it is associated with a reduction in&#xD;
      muscular mass, strength, functional capacity and quality of life, with an increment in&#xD;
      inflammatory and oxidative markers, and with a dysregulation of circulating miRNAs and its&#xD;
      target genes.&#xD;
&#xD;
      Animal and human studies have reported that some dietary components (macronutrients,&#xD;
      micronutrients and other bioactive substances) might restore these altered features.&#xD;
&#xD;
      Thus, we hypothesized that the intake of an oral nutritional supplement (ONS) specifically&#xD;
      developed for malnourished hemodialysis patients enriched with functional nutrients (extra&#xD;
      virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine, and with or&#xD;
      without probiotics) vs. individualized diet recommendations might:&#xD;
&#xD;
        -  Improve nutritional status (visceral proteins, muscular mass), functional capacity and&#xD;
           quality of life.&#xD;
&#xD;
        -  Reduce inflammatory and oxidative markers, and modulate the circulating levels of some&#xD;
           miRNAs and the expression of its target genes on cells. miRNAs may be useful biomarkers&#xD;
           to check the response to a nutritional intervention in malnourished hemodialysis&#xD;
           patients.&#xD;
&#xD;
      The present study is a randomized, multicenter, parallel-group trial with 3 groups, open to&#xD;
      the intake of ONS or individualized diet recommendations, but double-blind to the intake of&#xD;
      probiotics. Inclusion criteria comprised adult subjects (&gt;18 y/o) undergoing hemodialysis&#xD;
      more than 6 months previous at inclusion and at least one of these caloric malnutrition&#xD;
      criteria: a) involuntary weight loss &gt;5% in 3 months or &gt;10% in 6 months; b) serum albumin &lt;&#xD;
      3.5 g/dl or prealbumin &lt;28 mg/dl; c) body mass index (BMI) &lt; 23 kg/m2; d) muscular mass loss&#xD;
      &gt;5% in 3 months or &gt;10% in 6 months.&#xD;
&#xD;
      The study duration is 6 months, and comprises 4 visits (screening, basal, 3 months and 6&#xD;
      months). A nutritional examination that included anthropometric measurements, handgrip&#xD;
      strength measured by a hand dynamometer, body composition assessed by bioelectrical impedance&#xD;
      analysis (BIA) and a 5 days dietary record; quality of life evaluation by the &quot;12-item short&#xD;
      form health survey&quot;; the presence of symptoms of depression and anxiety (Hospital Anxiety and&#xD;
      Depression Scale); assessment of functional status by the &quot;Barthel&quot; test, the &quot;Short Physical&#xD;
      Performance Battery&quot; and the &quot;International Physical Activity Questionnaire&quot;; and blood and&#xD;
      stool samples will be obtained for each participant in each study visit (except screening&#xD;
      visit).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      The intake of an oral nutritional supplement (ONS) specifically developed for malnourished&#xD;
      hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3&#xD;
      fatty acids, whey protein, antioxidants, carnitine, and with or without probiotics) vs.&#xD;
      individualized diet recommendations might:&#xD;
&#xD;
        -  Improve nutritional status (visceral proteins, muscular mass), functional capacity and&#xD;
           quality of life.&#xD;
&#xD;
        -  Reduce inflammatory and oxidative markers, and modulate the circulating levels of some&#xD;
           miRNAs and the expression of its target genes on cells. miRNAs may be useful biomarkers&#xD;
           to check the response to a nutritional intervention in undernourished hemodialysis&#xD;
           patients.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      To evaluate:&#xD;
&#xD;
        -  The clinical response after the nutritional intervention:&#xD;
&#xD;
             1. Nutritional status: anthropometric measurements, handgrip strength measured by a&#xD;
                jamar hand dynamometer, body composition assessed by bioelectrical impedance&#xD;
                analysis (BIA), and a 5 days dietary record.&#xD;
&#xD;
             2. Functional status assessed by the &quot;Barthel&quot; test, the &quot;Short Physical Performance&#xD;
                Battery&quot; and the &quot;International Physical Activity Questionnaire&quot;.&#xD;
&#xD;
             3. Quality of life assessed by the &quot;12-item short form health survey&quot;, and the&#xD;
                presence of symptoms of depression and anxiety by the &quot;Hospital Anxiety and&#xD;
                Depression Scale&quot;.&#xD;
&#xD;
        -  The physiological response after the nutritional intervention:&#xD;
&#xD;
             1. Inflammatory markers.&#xD;
&#xD;
             2. Oxidative markers.&#xD;
&#xD;
             3. Gut microbiota.&#xD;
&#xD;
             4. Circulating miRNAs and the expression of its target genes on cells.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
        -  Randomized, multicenter, parallel-group trial with 3 groups, open to the intake of ONS&#xD;
           or diet, but double-blind to the intake of probiotics.&#xD;
&#xD;
        -  Study centers:&#xD;
&#xD;
             1. Hospital Regional Universitario de Málaga (Spain).&#xD;
&#xD;
             2. Hospital San Cecilio. Granada (Spain).&#xD;
&#xD;
             3. Hospital Rey Juan Carlos. Móstoles, Madrid (Spain).&#xD;
&#xD;
        -  One-hundred and twenty patients will be included. Eligible subjects will be invited to&#xD;
           participate, and written informed consent will be obtained before the inclusion.&#xD;
           Participants will be randomly assigned to one of these three groups:&#xD;
&#xD;
             1. ONS with probiotics. Dietary and physical activity recommendations.&#xD;
&#xD;
             2. ONS without probiotics. Dietary and physical activity recommendations.&#xD;
&#xD;
             3. Dietary and physical activity recommendations.&#xD;
&#xD;
        -  The study duration is 6 months, and comprises 4 visits (screening, basal, 3 months and 6&#xD;
           months). Recruitment period: 12 months.&#xD;
&#xD;
        -  Inclusion criteria: adult subjects (&gt;18 y/o) undergoing hemodialysis more than 6 months&#xD;
           previous at inclusion and at least one of these caloric malnutrition criteria: a)&#xD;
           involuntary weight loss &gt;5% in 3 months or &gt;10% in 6 months; b) serum albumin &lt; 3.5 g/dl&#xD;
           or prealbumin &lt;28 mg/dl; c) body mass index (BMI) &lt; 23 kg/m2; d) muscular mass loss &gt;5%&#xD;
           in 3 months or &gt;10% in 6 months.&#xD;
&#xD;
        -  A nutritional examination that included anthropometric measurements, handgrip strength&#xD;
           measured by a jamar hand dynamometer, body composition assessed by bioelectrical&#xD;
           impedance analysis (BIA) and a 5 days dietary record; quality of life evaluation by the&#xD;
           &quot;12-item short form health survey&quot;; the presence of symptoms of depression and anxiety&#xD;
           (Hospital Anxiety and Depression Scale); assessment of functional status by the&#xD;
           &quot;Barthel&quot; test, the &quot;Short Physical Performance Battery&quot; and the &quot;International Physical&#xD;
           Activity Questionnaire&quot;; and blood and stool samples will be obtained for each&#xD;
           participant in each study visit (except screening visit).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, multicenter, parallel-group trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Open to the intake of ONS or diet, but double-blind to the intake of probiotics</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Weight in kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fat free body mass</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Fat free body mass in kg assessed by bioelectrical impedance analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum albumin concentration</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Serum albumin in g/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum prealbumin concentration</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Serum prealbumin in mg/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in handgrip strength</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Handgrip strength in kg, measured by the jamar hydraulic hand dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the score of the &quot;Barthel&quot; test.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The Barthel is a 10-item ordinal scale that measures functional independence in the domains of personal care and mobility. Specifically, it measures self-care, sphincter management, transfers and locomotion. The score ranges between 0 and 100 points. Scores of 0-20 indicate &quot;total&quot; dependency, 21-60 indicate &quot;severe&quot; dependency, 61-90 indicate &quot;moderate&quot; dependency, 91-99 indicates &quot;slight&quot; dependency, and 100 indicates independency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the score of the Hospital Anxiety and Depression Scale (HADS).</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Symptoms of depression and anxiety assessed by the Hospital Anxiety and Depression Scale (HADS). This questionnaire comprises two sub-scales, each one range from 0 to 21 points; one assesses the symptoms of depression, and the other one the symptoms of anxiety. At each sub-scale, a score below 7 is considered normal range, between 8 and 10 means probable presence of depression or anxiety respectively, and more than 11 suggests the presence of depression or anxiety respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of high sensitivity C reactive protein (hs-CRP)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Plasma levels of high sensitivity C reactive protein (hs-CRP) in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of 8-iso-prostaglandina F2 α (8-iso-PGF2-α)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Plasma levels of 8-iso-prostaglandina F2 α (8-iso-PGF2-α) in pg/ml</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Malnutrition</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Oral nutritional supplement with probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics.&#xD;
Physical activity recommendations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral nutritional supplement without probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics.&#xD;
Physical activity recommendations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individualized dietary recommendations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individualized dietary recommendations. Physical activity recommendations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral nutritional supplement with probiotics</intervention_name>
    <description>Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.</description>
    <arm_group_label>Oral nutritional supplement with probiotics</arm_group_label>
    <other_name>Physical activity recommendations.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral nutritional supplement without probiotics</intervention_name>
    <description>Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.</description>
    <arm_group_label>Oral nutritional supplement without probiotics</arm_group_label>
    <other_name>Physical activity recommendations.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary recommendations</intervention_name>
    <description>Dietary recommendations</description>
    <arm_group_label>Individualized dietary recommendations</arm_group_label>
    <other_name>Physical activity recommendations.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects (&gt;18 y/o) undergoing hemodialysis more than 6 months previous at&#xD;
             inclusion.&#xD;
&#xD;
          -  At least one of these caloric malnutrition criteria: a) involuntary weight loss &gt;5% in&#xD;
             3 months or &gt;10% in 6 months; b) serum albumin &lt; 3.5 g/dl or prealbumin &lt;28 mg/dl; c)&#xD;
             body mass index (BMI) &lt; 23 kg/m2; d) muscular mass loss &gt;5% in 3 months or &gt;10% in 6&#xD;
             months.&#xD;
&#xD;
          -  Standard hemodialysis therapy (3 days/week, 240 min, high permeability dialyzer, blood&#xD;
             flow &gt;250 ml/min and dialysate flow 500 ml/min) or on-line hemodialysis therapy that&#xD;
             was not modified in the last 3 months previous to the inclusion.&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus or type 2 diabetes mellitus with HbA1c&gt;9%.&#xD;
&#xD;
          -  Unstable dry weight.&#xD;
&#xD;
          -  Limb amputation.&#xD;
&#xD;
          -  Significant edema.&#xD;
&#xD;
          -  Active malignancy.&#xD;
&#xD;
          -  Hospital admissions in the last 3 months.&#xD;
&#xD;
          -  Acute gastrointestinal disease in the 2 weeks before the inclusion.&#xD;
&#xD;
          -  Gastrectomy, gastroparesis or abnormal gastric emptying.&#xD;
&#xD;
          -  Acute heart failure grade IV.&#xD;
&#xD;
          -  Severe hepatic insufficiency (men gamma glutamyl transferase -GGT- &gt;150 U/l, women&#xD;
             &gt;120 U/l).&#xD;
&#xD;
          -  Alcohol or other drugs abuse.&#xD;
&#xD;
          -  Participants enrolled in other research study at inclusion.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  No informed consent obtained.&#xD;
&#xD;
          -  Patients who received any oral nutritional supplement (specific for hemodialysis&#xD;
             patients or not) in the 4 weeks before the inclusion.&#xD;
&#xD;
          -  Patients receiving enteral tube feeding.&#xD;
&#xD;
          -  Galactosemia, fructosemia, or requirement of a no fiber diet.&#xD;
&#xD;
          -  Allergy or hypersensitivity to any ingredient of the oral nutritional supplement.&#xD;
&#xD;
          -  Ongoing treatment with glucocorticoids.&#xD;
&#xD;
          -  Patients who received any oral fatty acids omega-3 supplement in the 4 weeks before&#xD;
             the inclusion.&#xD;
&#xD;
          -  Patients who received intradialytic parenteral nutrition in the 3 months before the&#xD;
             inclusion.&#xD;
&#xD;
          -  Patients who received any probiotics or prebiotics (not as part of the diet) in the 3&#xD;
             months before the inclusion.&#xD;
&#xD;
          -  Anemia (Hemoglobin &lt; 10 g/dl) or Epoetin resistance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Olveira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación biomédica de Málaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Cecilio</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will be published when the trial will be finished.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

